Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Japanese Ministry Of Health Approves Rasilez(R), A First-in-class Direct Renin Inhibitor (DRI), For The Treatment Of High Blood Pressure
Rasilez® (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin9, an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines.
generic viagra online
Hunt For Blood Test To Determine Melanoma Survival Rates
Research at the University of Leicester will be breaking new ground in the search for a simple blood test that could tell whether a patient with melanoma has the condition in an aggressive form. Melanoma is the most aggressive form of skin cancer. Staging, which involves determining the size of the tumour and its extent of spread, is the best predictor of whether a patient will succumb to disease or survive.
News of the day
When Summer Vacation Is Far From A Vacation
The kids are playing in the backyard and enjoying their break from school. Your husband is enjoying the day on the golf course. And you"re cleaning up the house, folding laundry and cooking three meals. Sound familiar?
Oncology

Amgen Grant To Study Treatments For Older Leukemia Patients Received By Loyola Fellow

Dr. Aileen Go of Loyola University Health System, who is studying treatment options for older leukemia and lymphoma patients, has won a prestigious Amgen Foundation Fellowship grant. Go, a second-year fellow in hematology/oncology, will work with Dr. Patrick Stiff, director of Loyola"s Cardinal Bernardin Cancer Center. Stiff and Go are studying the use of umbilical cord blood transplants grown from cord blood cells outside the body. The transplants are intended for patients ages 55 to 75, who previously have been excluded from such treatments. Patients will receive high-dose chemotherapy, which, in addition to killing cancer cells also destroys the patient"s immune system cells. To build a new immune system, patients receive transplanted stem cells, which develop into new immune system cells. Older patients generally cannot tolerate high-dose chemotherapy. Go and Stiff will study a reduced-intensity chemotherapy regimen, as well as a method for boosting the number of stem cells. The stem cells will come from donated umbilical cord blood. A newborn"s cord blood does not contain enough stem cells for most adult patients. So the cord blood will be sent to a lab that will grow more stem cells prior to the transplant. The Amgen Foundation provides grants for such purposes as advancing science education and improving the quality of care and access for patients. The one-year award that Go received is given to medical researchers who are beginning to pursue academic careers. "These are very competitive, with the majority of the awards going to MDs and PhDs who submit truly amazing projects for funding," Stiff said. Dr. Paul Whelton, president and CEO of Loyola University Health System, added that Loyola is "a home for the next generation of leaders -- those who will make a difference in reducing the burden of illness in society." Jim Ritter Loyola University Health System


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009